T1	PROC 46 60	Ensayo clínico
#1	AnnotatorNotes T1	C0008976; Clinical Trials; Research Activity
T2	PROC 67 98	evaluar la eficacia y seguridad
#2	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
T3	CHEM 102 113	tocilizumab
#3	AnnotatorNotes T3	C1609165; tocilizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	PROC 120 131	tratamiento
#4	AnnotatorNotes T4	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T5	DISO 149 170	neumonía por COVID-19
T6	PROC 212 250	Ensayo clínico abierto y multicéntrico
T7	PROC 256 290	evaluar la efectividad y seguridad
T8	CHEM 294 305	tocilizumab
#5	AnnotatorNotes T8	C1609165; tocilizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	PROC 324 335	tratamiento
#6	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	DISO 353 374	neumonía por COVID-19
T11	DISO 417 438	Neumonía por COVID-19
T12	PROC 480 504	consentimiento informado
#7	AnnotatorNotes T12	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T13	PROC 573 586	Diagnosticado
#8	AnnotatorNotes T13	C0011900; Diagnosis; Diagnostic Procedure
T14	DISO 591 612	neumonía por COVID-19
T15	CHEM 662 673	tocilizumab
#9	AnnotatorNotes T15	C1609165; tocilizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T16	PROC 742 753	tratamiento
#10	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	PROC 773 786	Hospitalizado
#11	AnnotatorNotes T17	C0019993; Hospitalization; Health Care Activity
T18	PROC 789 808	ingresado en la UCI
#12	AnnotatorNotes T18	C0583239; Admission to intensive care unit; Health Care Activity
T19	DISO 870 885	afección médica
T20	CHEM 904 914	medicación
#13	AnnotatorNotes T20	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T21	DISO 1032 1052	Reacciones alérgicas
#14	AnnotatorNotes T21	C1527304; Allergic Reaction; Pathologic Function
T22	CHEM 1072 1083	tocilizumab
#15	AnnotatorNotes T22	C1609165; tocilizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T23	CHEM 1092 1116	anticuerpos monoclonales
#16	AnnotatorNotes T23	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T24	DISO 1120 1138	Infecciones agudas
#17	AnnotatorNotes T24	C0275518; Acute infectious disease; Disease or Syndrome
T25	DISO 1169 1190	infección tuberculosa
#18	AnnotatorNotes T25	C0041296; Tuberculosis; Disease or Syndrome
T26	PROC 1219 1237	prueba de embarazo
#19	AnnotatorNotes T26	C0032976; Pregnancy Tests; Diagnostic Procedure
T27	PROC 617 623	RT-PCR
#20	AnnotatorNotes T27	C0599161; Reverse Transcriptase Polymerase Chain Reaction; Molecular Biology Research Technique
T28	CHEM 758 769	tocilizumab
#21	AnnotatorNotes T28	C1609165; tocilizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T29	PROC 1253 1259	examen
#22	AnnotatorNotes T29	C0582103; Medical Examination; Health Care Activity
T30	Date 13 17	2020
T31	LIVB 135 144	pacientes
#23	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	Route 306 317	intravenoso
#24	AnnotatorNotes T32	C1522726; Intravenous Route of Drug Administration; Functional Concept
T33	LIVB 339 348	pacientes
#25	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T35	Age 545 561	Al menos 18 años
T36	CONC 645 658	primera dosis
T37	Duration 674 695	un máximo de dos días
T38	LIVB 840 848	paciente
#26	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	LIVB 955 967	investigador
#27	AnnotatorNotes T39	C0035173; Research Personnel; Professional or Occupational Group
T40	LIVB 998 1006	paciente
#28	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	LIVB 1207 1215	lactante
#29	AnnotatorNotes T41	C4316174; Patients who are breastfeeding; Patient or Disabled Group
T42	LIVB 1194 1204	Embarazada
#30	AnnotatorNotes T42	C0033011; Pregnant Women; Population Group
T43	PHYS 1229 1237	embarazo
#31	AnnotatorNotes T43	C0032961; Pregnancy; Organism Function
A1	Status T21 History_of
#32	AnnotatorNotes T6	C1709323; Open Label Study; Research Activity + C1096776; Multicenter Study; Research Activity
#33	AnnotatorNotes T5	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#34	AnnotatorNotes T10	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#35	AnnotatorNotes T11	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#36	AnnotatorNotes T14	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#37	AnnotatorNotes T19	C4745084; Medical Condition; Finding
T34	Spec_cue 932 938	podría
T44	Observation 969 993	comprometer la seguridad
A2	Assertion T44 Speculated
T45	Observation 1009 1028;969 980	los datos obtenidos comprometer
A3	Assertion T45 Speculated
T46	Quantifier_or_Qualifier 1148 1155	activas
#38	AnnotatorNotes T46	C0679217; Active State; Idea or Concept
R1	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T46	
T47	Quantifier_or_Qualifier 1141 1147	graves
#39	AnnotatorNotes T47	C1547227; Severe - Severity of Illness Code; Intellectual Product
R2	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T47	
T48	Quantifier_or_Qualifier 1053 1059	graves
#40	AnnotatorNotes T48	C1547227; Severe - Severity of Illness Code; Intellectual Product
R3	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T48	
A4	Status T48 History_of
T49	CONC 708 717	inclusión
#41	AnnotatorNotes T49	C1512693; Inclusion Criteria; Qualitative Concept
R4	Before Arg1:T15 Arg2:T49	
R5	Used_for Arg1:T28 Arg2:T16	
R6	Has_Dose_or_Strength Arg1:T15 Arg2:T36	
R7	Has_Duration_or_Interval Arg1:T15 Arg2:T37	
R8	Used_for Arg1:T3 Arg2:T4	
R9	Experiences Arg1:T31 Arg2:T3	
R10	Experiences Arg1:T31 Arg2:T5	
R11	Experiences Arg1:T33 Arg2:T8	
R12	Used_for Arg1:T8 Arg2:T9	
R13	Has_Route_or_Mode Arg1:T8 Arg2:T32	
R14	Experiences Arg1:T33 Arg2:T10	
T50	Quantifier_or_Qualifier 505 509	oral
#42	AnnotatorNotes T50	C0439824; Verbal; Qualitative Concept
R15	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T50	
R16	Overlap Arg1:T14 Arg2:T27	
R17	Before Arg1:T27 Arg2:T13	
R18	Experiences Arg1:T38 Arg2:T19	
R19	Experiences Arg1:T38 Arg2:T20	
T51	Quantifier_or_Qualifier 915 927	concomitante
#43	AnnotatorNotes T51	C0521115; Simultaneous; Temporal Concept
R20	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T51	
R21	Before Arg1:T20 Arg2:T45	
R22	Before Arg1:T20 Arg2:T44	
R23	Speculation Arg1:T34 Arg2:T44	
R24	Speculation Arg1:T34 Arg2:T45	
R25	Experiences Arg1:T40 Arg2:T19	
R26	Experiences Arg1:T40 Arg2:T20	
R27	Causes Arg1:T22 Arg2:T21	
R28	Causes Arg1:T23 Arg2:T21	
R29	Experiences Arg1:T42 Arg2:T43	
R31	Overlap Arg1:T26 Arg2:T29	
T52	CONC 1272 1277	dosis
#44	AnnotatorNotes T52	C0178602; Dosage; Quantitative Concept
R32	Before Arg1:T29 Arg2:T52	
R33	Before Arg1:T26 Arg2:T52	
T53	Result_or_Value 1238 1246	positiva
#45	AnnotatorNotes T53	C1446409; Positive; Finding
R34	Experiences Arg1:T42 Arg2:T26	
R35	Has_Result_or_Value Arg1:T26 Arg2:T53	
T54	Observation 515 541	participar en este estudio
#46	AnnotatorNotes T54	C1278516; Patient participation status; Finding (?)
R36	Before Arg1:T12 Arg2:T54	
#47	AnnotatorNotes T7	C0511730; Identify product efficacy and safety issues; Health Care Activity
R30	Experiences Arg1:T42 Arg2:T29	
#48	AnnotatorNotes R6	(?)
#49	AnnotatorNotes T36	C5236155; Date of First Dose; Temporal Concept
A5	Status T16 Future
A6	Status T28 Future
A7	Experiencer T31 Patient
A8	Experiencer T33 Patient
A9	Experiencer T38 Patient
A10	Experiencer T39 Other
A11	Experiencer T40 Patient
A12	Experiencer T42 Patient
A13	Experiencer T41 Patient
